Patrick John Finn Sells 2,311 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,311 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $85,807.43. Following the completion of the transaction, the chief operating officer now owns 173,895 shares in the company, valued at approximately $6,456,721.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 23rd, Patrick John Finn sold 2,174 shares of Twist Bioscience stock. The shares were sold at an average price of $30.12, for a total value of $65,480.88.
• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total transaction of $16,108.08.

Twist Bioscience Trading Down 4.0 %

Twist Bioscience stock opened at $41.40 on Thursday. The firm has a 50 day simple moving average of $34.18 and a 200 day simple moving average of $31.59. Twist Bioscience Co. has a 1-year low of $11.81 and a 1-year high of $44.92. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.32 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same quarter last year, the company earned ($1.06) EPS. The firm’s revenue was up 25.1% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience Co. will post -3.17 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Robert W. Baird lifted their target price on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Scotiabank increased their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday. Finally, Barclays upped their price objective on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $42.50.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Federated Hermes Inc. purchased a new position in Twist Bioscience during the third quarter worth about $29,000. China Universal Asset Management Co. Ltd. raised its stake in Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the fourth quarter valued at approximately $30,000. Allspring Global Investments Holdings LLC grew its stake in Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Twist Bioscience in the 1st quarter worth $124,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.